The Generic Pharmaceutical Association (GPhA) has hired Ahaviah Glaser as vice president for policy and strategic alliances.


Generic Pharmaceutical Association, GPhA, Ahaviah Glaser, vice president for policy and strategic alliances, generic medicines, generic pharmaceutical, generic biologics, Ralph Neas, Affordable Medicines Research Institute, AMR Institute, health care




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

GPhA names VP of policy and alliances

December 8th, 2011

WASHINGTON – The Generic Pharmaceutical Association (GPhA) has hired Ahaviah Glaser as vice president for policy and strategic alliances.

GPhA said Thursday that Glaser, who joined the association late last month, previously served on AARP's government affairs team and the Law & Government Program of American University's Washington College of Law.

Her hiring marks a key step in GPhA's plan to use research and strategic alliances to ensure that the importance of generic medicines is widely understood, especially in emerging opportunities such as generic biologics, the association noted.

"Through GPhA and the newly created Affordable Medicines Research Institute (AMR Institute), Havi will help educate both the public at large and policy makers around the world about the safety and efficacy of generic medicines as well as the extraordinary health care savings that generics provide," GPhA president and chief executive officer Ralph Neas said in a statement.

"In a time when budget challenges and health care costs are colliding as never before, not only for governments but for families, Havi's job will be to help shepherd research, education and outreach efforts to ensure that all Americans fully understand that generic pharmaceuticals reduce health care costs while maintaining the high-quality standard of care that they rightly expect," Neas added.

GPhA cited Glaser's wide-ranging background. As an attorney, she has litigated key cases in the private sector, lobbied Congress, drafted legislation, worked with regulatory agencies and led diverse coalitions, all to expand access to safe, affordable prescription medication, the association said. She is also an experienced educator, most recently serving as an adjunct professor in the Washington College of Law's Health Law and Policy Institute since 2006. Immediately before coming to GPhA, Glaser served as AARP's lead lobbyist on Medicare, Medicaid and pharmaceutical policy.

Advertisement